Drug loaded implantable devices to treat cardiovascular disease

ABSTRACT Introduction It is widely acknowledged that cardiovascular diseases (CVDs) continue to be the leading cause of death globally. Furthermore, CVDs are the leading cause of diminished quality of life for patients, frequently as a result of their progressive deterioration. Medical implants that release drugs into the body are active implants that do more than just provide mechanical support; they also have a therapeutic role. Primarily, this is achieved through the controlled release of active pharmaceutical ingredients (API) at the implementation site. Areas covered In this review, the authors discuss drug-eluting stents, drug-eluting vascular grafts, and drug-eluting cardiac patches with the aim of providing a broad overview of the three most common types of cardiac implant. Expert opinion Drug eluting implants are an ideal alternative to traditional drug delivery because they allow for accurate drug release, local drug delivery to the target tissue, and minimize the adverse side effects associated with systemic administration. Despite the fact that there are still challenges that need to be addressed, the ever-evolving new technologies are making the fabrication of drug-eluting implants a rewarding therapeutic endeavor with the possibility for even greater advances.

[1]  Yuanjin Zhao,et al.  Bioinspired Vascular Stents with Microfluidic Electrospun Multilayer Coatings for Preventing In‐Stent Restenosis , 2022, Advanced healthcare materials.

[2]  Q. Tarrés,et al.  TPU-based antiplatelet cardiovascular prosthesis prepared using fused deposition modelling , 2022, Materials & Design.

[3]  Chenguang Li,et al.  A TEMPOL and rapamycin loaded nanofiber-covered stent favors endothelialization and mitigates neointimal hyperplasia and local inflammation , 2022, Bioactive materials.

[4]  M. Ali,et al.  Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach , 2022, Journal of Cardiothoracic Surgery.

[5]  Li Yang,et al.  A Polyphenol-Network-Mediated Coating Modulates Inflammation and Vascular Healing on Vascular Stents. , 2022, ACS nano.

[6]  Steven M. Tommasini,et al.  Interpretation of regulatory factors for 3D printing at hospitals and medical centers, or at the point of care , 2022, 3D Printing in Medicine.

[7]  L. P. Tan,et al.  Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation. , 2022, Nanomedicine.

[8]  Tianfeng Zhou,et al.  A Review on Manufacturing and Post-Processing Technology of Vascular Stents , 2022, Micromachines.

[9]  K. Storey,et al.  MicroRNA Cues from Nature: A Roadmap to Decipher and Combat Challenges in Human Health and Disease? , 2021, Cells.

[10]  D. Lamprou,et al.  Development of drug loaded cardiovascular prosthesis for thrombosis prevention using 3D printing , 2021, Materials science & engineering. C, Materials for biological applications.

[11]  M. Rahimi,et al.  Biodegradable Drug-eluting Nanofiber-loaded Vascular Graft , 2021 .

[12]  A. Concheiro,et al.  Use of 3D Printing for the Development of Biodegradable Antiplatelet Materials for Cardiovascular Applications , 2021, Pharmaceuticals.

[13]  E. Michalopoulos,et al.  Future Perspectives in Small-Diameter Vascular Graft Engineering , 2020, Bioengineering.

[14]  K. Cheng,et al.  Recent Development in Therapeutic Cardiac Patches , 2020, Frontiers in Cardiovascular Medicine.

[15]  C. Park,et al.  Considerations in the Development of Small-Diameter Vascular Graft as an Alternative for Bypass and Reconstructive Surgeries: A Review , 2020, Cardiovascular Engineering and Technology.

[16]  M. Pereira,et al.  In vitro controlled release of extracellular vesicles for cardiac repair from poly(glycerol sebacate) acrylate-based polymers. , 2020, Acta biomaterialia.

[17]  Lei Zhang,et al.  Shapeable large-pore electrospun polycaprolactam cotton facilitates the rapid formation of a functional tissue engineered vascular graft , 2020, Materials & Design.

[18]  Brian C. Case,et al.  The Orsiro ultrathin, bioresorbable-polymer sirolimus-eluting stent: A review of current evidence. , 2020, Cardiovascular revascularization medicine : including molecular interventions.

[19]  Yi Hong,et al.  Current Advances in Biodegradable Synthetic Polymer based Cardiac Patches. , 2020, Journal of biomedical materials research. Part A.

[20]  D. Kumbhani,et al.  The Current Literature on Bioabsorbable Stents: a Review , 2019, Current Atherosclerosis Reports.

[21]  Hyoun‐Ee Kim,et al.  Fabrication of strong, bioactive vascular grafts with PCL/collagen and PCL/silica bilayers for small-diameter vascular applications , 2019, Materials & Design.

[22]  Justin J Chung,et al.  The effect of Substance P/Heparin conjugated PLCL polymer coating of bioinert ePTFE vascular grafts on the recruitment of both ECs and SMCs for accelerated regeneration , 2019, Scientific Reports.

[23]  V. Fuster,et al.  The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond. , 2019, Journal of the American College of Cardiology.

[24]  Alice Rita Salgarella,et al.  Small-caliber vascular grafts based on a piezoelectric nanocomposite elastomer: Mechanical properties and biocompatibility. , 2019, Journal of the mechanical behavior of biomedical materials.

[25]  S. Saito,et al.  Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents. , 2019, Circulation. Cardiovascular interventions.

[26]  Junnan Tang,et al.  microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential. , 2019, The Journal of clinical investigation.

[27]  D. Ding,et al.  An in Vivo miRNA Delivery System for Restoring Infarcted Myocardium. , 2019, ACS nano.

[28]  M. King,et al.  Engineering small-caliber vascular grafts from collagen filaments and nanofibers with comparable mechanical properties to native vessels , 2019, Biofabrication.

[29]  Fabio Bernini,et al.  MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs , 2019, Nature.

[30]  Prabhanjan S. Giram,et al.  Clopidogrel eluting electrospun polyurethane/polyethylene glycol thromboresistant, hemocompatible nanofibrous scaffolds , 2019, Journal of biomaterials applications.

[31]  Song Li,et al.  Regeneration of a neoartery through a completely autologous acellular conduit in a minipig model: a pilot study , 2019, Journal of Translational Medicine.

[32]  A. Shamloo,et al.  Bilayered heparinized vascular graft fabricated by combining electrospinning and freeze drying methods. , 2019, Materials science & engineering. C, Materials for biological applications.

[33]  F. Vogt,et al.  The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement? , 2018, Journal of cellular and molecular medicine.

[34]  John Canfield,et al.  40 Years of Percutaneous Coronary Intervention: History and Future Directions , 2018, Journal of personalized medicine.

[35]  A. Jaggi,et al.  Clinical evidence and mechanisms of growth factors in idiopathic and diabetes‐induced carpal tunnel syndrome , 2018, European journal of pharmacology.

[36]  S. Hassanajili,et al.  Cardiovascular stents: overview, evolution, and next generation , 2018, Progress in Biomaterials.

[37]  E. Brey,et al.  Endothelialization mechanisms in vascular grafts , 2018, Journal of tissue engineering and regenerative medicine.

[38]  Haitao Cui,et al.  3D bioprinting for cardiovascular regeneration and pharmacology☆ , 2018, Advanced drug delivery reviews.

[39]  K. Stangl,et al.  Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent: 5-Year Outcomes of the Randomized BIOFLOW-II Trial. , 2018, JACC. Cardiovascular interventions.

[40]  I. Meredith,et al.  Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[41]  Shunichi Homma,et al.  Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells , 2018, Nature Biomedical Engineering.

[42]  Seung‐Jung Park,et al.  Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. , 2018, Journal of the American College of Cardiology.

[43]  E. Coy,et al.  Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications , 2018, Pharmaceutical Research.

[44]  A. Colombo,et al.  Bioresorbable Scaffolds: A Complex Journey to the "Promised Land". , 2017, JACC. Cardiovascular interventions.

[45]  R. Waksman A new generation of drug-eluting stents: Indications and outcomes of bioresorbable vascular scaffolds , 2017, Cleveland Clinic Journal of Medicine.

[46]  G. Stone,et al.  6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study. , 2017, JACC. Cardiovascular interventions.

[47]  Guixue Wang,et al.  Design, preparation and performance of a novel drug-eluting stent with multiple layer coatings. , 2017, Biomaterials science.

[48]  Milica Radisic,et al.  Flexible shape-memory scaffold for minimally invasive delivery of functional tissues. , 2017, Nature materials.

[49]  M. Leoncini,et al.  Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives. , 2017, Journal of thoracic disease.

[50]  Li-Zhong Sun,et al.  In vitro and in vivo evaluation of a small-caliber coaxial electrospun vascular graft loaded with heparin and VEGF. , 2017, International journal of surgery.

[51]  A. Colombo,et al.  Should We Still Have Bare-Metal Stents Available in Our Catheterization Laboratory? , 2017, Journal of the American College of Cardiology.

[52]  Antonio Colombo,et al.  New generation bioresorbable scaffold technologies: an update on novel devices and clinical results. , 2017, Journal of thoracic disease.

[53]  C. Di Mario,et al.  The DESolve novolimus bioresorbable Scaffold: from bench to bedside. , 2017, Journal of thoracic disease.

[54]  K. Dawkins,et al.  Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents , 2017, Current cardiology reviews.

[55]  S. Bangalore,et al.  Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. , 2017, JACC. Cardiovascular interventions.

[56]  Freya J. I. Fowkes,et al.  Peripheral artery disease: epidemiology and global perspectives , 2017, Nature Reviews Cardiology.

[57]  Deepak L. Bhatt,et al.  New-Generation Coronary Stents: Current Data and Future Directions , 2017, Current Atherosclerosis Reports.

[58]  N. Bursac,et al.  Tissue-engineered 3-dimensional (3D) microenvironment enhances the direct reprogramming of fibroblasts into cardiomyocytes by microRNAs , 2016, Scientific Reports.

[59]  Ali Khademhosseini,et al.  Direct 3D bioprinting of perfusable vascular constructs using a blend bioink. , 2016, Biomaterials.

[60]  Bernardo Cortese,et al.  Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. , 2016, Journal of thoracic disease.

[61]  R. Piccolo,et al.  The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence , 2016, International journal of molecular sciences.

[62]  Uma Maheswari Krishnan,et al.  Engineering a growth factor embedded nanofiber matrix niche to promote vascularization for functional cardiac regeneration. , 2016, Biomaterials.

[63]  K. Woodrow,et al.  In pursuit of functional electrospun materials for clinical applications in humans. , 2016, Therapeutic delivery.

[64]  Patrick K. Bowen,et al.  Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn‐Alloys , 2016, Advanced healthcare materials.

[65]  C. Indolfi,et al.  MicroRNAs for Restenosis and Thrombosis After Vascular Injury. , 2016, Circulation research.

[66]  R. Costa,et al.  Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions. , 2016, JACC. Cardiovascular interventions.

[67]  Assaf Shapira,et al.  Engineered hybrid cardiac patches with multifunctional electronics for online monitoring and regulation of tissue function , 2016, Nature materials.

[68]  Aaron Tan,et al.  Coating Techniques and Release Kinetics of Drug-Eluting Stents. , 2016, Journal of medical devices.

[69]  Bhavik J. Pandya,et al.  Biodegradable polymer stents vs second generation drug eluting stents: A meta-analysis and systematic review of randomized controlled trials. , 2016, World journal of cardiology.

[70]  Y U Lee,et al.  3D‐Printed Biodegradable Polymeric Vascular Grafts , 2016, Advanced healthcare materials.

[71]  Soo Teik Lim,et al.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial , 2016, The Lancet.

[72]  M. Trombetta,et al.  Preliminary In Vivo Evaluation of a Hybrid Armored Vascular Graft Combining Electrospinning and Additive Manufacturing Techniques , 2016, Drug target insights.

[73]  G. Galyfos,et al.  Bioabsorbable stenting in peripheral artery disease. , 2015, Cardiovascular revascularization medicine : including molecular interventions.

[74]  J. Fradette,et al.  Human adipose-derived stromal cells for the production of completely autologous self-assembled tissue-engineered vascular substitutes. , 2015, Acta biomaterialia.

[75]  C. Hehrlein Drug‐coated balloons—the importance of packing and dosing antiproliferative drugs , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[76]  Charanpreet Singh,et al.  Medical Textiles as Vascular Implants and Their Success to Mimic Natural Arteries , 2015, Journal of functional biomaterials.

[77]  P. Serruys,et al.  Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents , 2015, Circulation. Cardiovascular interventions.

[78]  J. Golledge,et al.  A Review of the Pathophysiology and Potential Biomarkers for Peripheral Artery Disease , 2015, International journal of molecular sciences.

[79]  Binita Shah,et al.  Drug-Eluting Stents: the Past, Present, and Future , 2015, Current Atherosclerosis Reports.

[80]  Yingying Huang,et al.  Drug-eluting biostable and erodible stents. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Jyothi U. Menon,et al.  Electrospun biodegradable elastic polyurethane scaffolds with dipyridamole release for small diameter vascular grafts. , 2014, Acta biomaterialia.

[82]  T. Tuschl,et al.  A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. , 2014, The Journal of clinical investigation.

[83]  Michael Joner,et al.  Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. , 2013, JACC. Cardiovascular interventions.

[84]  A. Domb,et al.  Eluting combination drugs from stents. , 2013, International journal of pharmaceutics.

[85]  E. Vittinghoff,et al.  Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: Insights from the Heart and Soul Study , 2013, Vascular medicine.

[86]  Patrick W. Serruys,et al.  Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro , 2013 .

[87]  P. Serruys,et al.  Coronary stents: historical development, current status and future directions. , 2013, British medical bulletin.

[88]  P. Serruys,et al.  Progress in treatment by percutaneous coronary intervention: the stent of the future. , 2013, Revista espanola de cardiologia.

[89]  Graça Raposo,et al.  Extracellular vesicles: Exosomes, microvesicles, and friends , 2013, The Journal of cell biology.

[90]  R. Applegate,et al.  Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform , 2013, Clinical Medicine Insights. Cardiology.

[91]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[92]  J. Fajadet,et al.  Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. , 2012, Journal of the American College of Cardiology.

[93]  Yiannis S. Chatzizisis,et al.  Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. , 2012, Journal of the American College of Cardiology.

[94]  Michail I. Papafaklis,et al.  Drug-eluting stent restenosis: effect of drug type, release kinetics, hemodynamics and coating strategy. , 2012, Pharmacology & therapeutics.

[95]  P. Tsao,et al.  MicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion , 2012, Science Translational Medicine.

[96]  Kevin Croce,et al.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. , 2011, JACC. Cardiovascular interventions.

[97]  Gregg W Stone,et al.  Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. , 2011, Journal of the American College of Cardiology.

[98]  K. Seung,et al.  Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. , 2011, The American journal of cardiology.

[99]  I. Pipinos,et al.  The Myopathy of Peripheral Arterial Occlusive Disease: Part 1. Functional and Histomorphological Changes and Evidence for Mitochondrial Dysfunction , 2008, Vascular and endovascular surgery.

[100]  S. Gidding,et al.  Preventing Heart Disease in the 21st Century: Implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Study , 2008, Circulation.

[101]  P. Serruys,et al.  The future of drug-eluting stents. , 2008, Pharmacological research.

[102]  A R Boccaccini,et al.  Myocardial tissue engineering: a review , 2007, Journal of tissue engineering and regenerative medicine.

[103]  J. Sear,et al.  Coronary artery stents and non-cardiac surgery. , 2007, British journal of anaesthesia.

[104]  A. Wieczorek,et al.  Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. , 2007, Journal of the American College of Cardiology.

[105]  Christopher Breuer,et al.  Artificial blood vessel: the Holy Grail of peripheral vascular surgery. , 2005, Journal of vascular surgery.

[106]  Y. Dzenis,et al.  Spinning Continuous Fibers for Nanotechnology , 2004, Science.

[107]  E. Grech,et al.  Percutaneous coronary intervention. I: History and development , 2003, BMJ : British Medical Journal.

[108]  H. Nilsson,et al.  Vasomotion: mechanisms and physiological importance. , 2003, Molecular interventions.

[109]  J. Miller,et al.  Long‐term results of femorotibial bypass with vein or polytetrafluoroethylene , 1998, The British journal of surgery.

[110]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[111]  Dawei Jin,et al.  Preliminary application of a cell-free mono-layered vascular scaffold in a rabbit model , 2021 .

[112]  StéphaneCook,et al.  Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent , 2015 .

[113]  T. Simard,et al.  The evolution of coronary stents: a brief review. , 2014, The Canadian journal of cardiology.

[114]  C. Grines,et al.  Bioresorbable Scaffolds. , 2014, Interventional cardiology.

[115]  P. Serruys,et al.  Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[116]  A. Seth Moving Towards Biomimicry - The Development of the Novel BioMime™ Sirolimus-eluting Coronary Stent System Interventional Cardiology , 2010 .

[117]  Elliot L Chaikof,et al.  Biomaterials for vascular tissue engineering. , 2010, Regenerative medicine.

[118]  W. Insull The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. , 2009, The American journal of medicine.